Work

Reply: Chronic Obstructive Pulmonary Disease Readmissions and Medicare Reimbursement

Year: 2014

Type: letter

Abstract: month of ivacaftor, so the investigators concluded that this therapy could possibly delay or prevent the development of CFRD in at-risk patients (4).On the basis of our experience with the patient described here, ivacaftor can potentially lead to the resolution of CFRD.Clinicians should be aware of this important potential benefit not only as a means to potentially delay or prevent the development of CFRD but also to correct well-established CFRD.

Source: American Journal of Respiratory and Critical Care Medicine

DOI: 10.1164/rccm.201404-0635le

Authors: Laura C. Feemster, David H. Au

Institutions: University of Washington, VA Puget Sound Health Care System

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Veterans Affairs, National Institutes of Health, National Heart, Lung, and Blood Institute